Aaron R. Hansen

20.5k total citations · 6 hit papers
328 papers, 7.8k citations indexed

About

Aaron R. Hansen is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Aaron R. Hansen has authored 328 papers receiving a total of 7.8k indexed citations (citations by other indexed papers that have themselves been cited), including 168 papers in Oncology, 157 papers in Pulmonary and Respiratory Medicine and 86 papers in Cancer Research. Recurrent topics in Aaron R. Hansen's work include Cancer Immunotherapy and Biomarkers (91 papers), Cancer Genomics and Diagnostics (77 papers) and Renal cell carcinoma treatment (52 papers). Aaron R. Hansen is often cited by papers focused on Cancer Immunotherapy and Biomarkers (91 papers), Cancer Genomics and Diagnostics (77 papers) and Renal cell carcinoma treatment (52 papers). Aaron R. Hansen collaborates with scholars based in Canada, United States and Australia. Aaron R. Hansen's co-authors include Lillian L. Siu, Philippe L. Bédard, Mark J. Ratain, Daphne Day, Tom Wei‐Wu Chen, L.L. Siu, Leila Khoja, Wei Xu, Sarah Picardo and Sarina A. Piha‐Paul and has published in prestigious journals such as Nature, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Aaron R. Hansen

309 papers receiving 7.7k citations

Hit Papers

Tumour heterogeneity in the clinic 2013 2026 2017 2021 2013 2017 2020 2015 2017 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Tumour heterogeneity in the clinic
    2013 897 citations Philippe L. Bédard, Aaron R. Hansen et al. profile →
  2. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review
    2017 678 citations L.L. Siu, Aaron R. Hansen et al. profile →
  3. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE‐158 and KEYNOTE‐028 studies
    2020 335 citations Hyun Cheol Chung, Aaron R. Hansen et al. International Journal of Cancer profile →
  4. Refining American Joint Committee on Cancer/Union for International Cancer Control TNM Stage and Prognostic Groups for Human Papillomavirus–Related Oropharyngeal Carcinomas
    2015 301 citations Shao Hui Huang, Wei Xu et al. Journal of Clinical Oncology profile →
  5. Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study
    2017 300 citations Alain P. Algazi, Aaron R. Hansen et al. Journal of Clinical Oncology profile →
  6. Pembrolizumab in Patients With Microsatellite Instability–High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study
    2022 273 citations Aaron R. Hansen, Wilson H. Miller et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Aaron R. Hansen Canada 39 4.2k 2.5k 2.0k 1.8k 1.5k 328 7.8k
Christophe Le Tourneau France 46 4.9k 1.2× 2.3k 0.9× 1.3k 0.7× 2.1k 1.2× 1.6k 1.1× 335 8.7k
Stephen Y. Lai United States 51 2.7k 0.7× 1.9k 0.7× 2.0k 1.0× 1.9k 1.1× 1.1k 0.7× 271 8.3k
Sylvie Rottey Belgium 39 4.1k 1.0× 3.1k 1.2× 1.6k 0.8× 2.2k 1.2× 949 0.6× 236 7.9k
Amanda Psyrri Greece 48 3.7k 0.9× 1.7k 0.7× 1.4k 0.7× 2.5k 1.4× 1.5k 1.0× 251 7.2k
Carla M.L. van Herpen Netherlands 44 3.6k 0.9× 1.9k 0.7× 1.1k 0.6× 1.9k 1.1× 707 0.5× 225 6.6k
A. Dimitrios Colevas United States 51 3.4k 0.8× 2.1k 0.8× 2.2k 1.1× 1.6k 0.9× 582 0.4× 197 7.6k
Lars Bastholt Denmark 42 4.2k 1.0× 1.7k 0.7× 1.3k 0.7× 1.8k 1.0× 660 0.4× 183 8.3k
Denis Soulières Canada 41 3.9k 0.9× 3.3k 1.3× 1.5k 0.8× 1.9k 1.1× 946 0.6× 258 7.5k
Stefan M. Willems Netherlands 41 2.3k 0.5× 1.3k 0.5× 1.2k 0.6× 1.7k 1.0× 1.4k 0.9× 222 5.6k
Jonathan D. Cheng United States 43 8.8k 2.1× 3.3k 1.3× 2.3k 1.2× 2.3k 1.3× 2.2k 1.5× 113 12.0k

Countries citing papers authored by Aaron R. Hansen

Since Specialization
Citations

This map shows the geographic impact of Aaron R. Hansen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aaron R. Hansen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aaron R. Hansen more than expected).

Fields of papers citing papers by Aaron R. Hansen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aaron R. Hansen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aaron R. Hansen. The network helps show where Aaron R. Hansen may publish in the future.

Co-authorship network of co-authors of Aaron R. Hansen

This figure shows the co-authorship network connecting the top 25 collaborators of Aaron R. Hansen. A scholar is included among the top collaborators of Aaron R. Hansen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aaron R. Hansen. Aaron R. Hansen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mittal, Abhenil, Zachary Veitch, Vikaash Kumar, et al.. (2024). The Survival Outcomes of the Metastatic Nonclear Cell Renal Cell Carcinoma in the Immunotherapy Era: Princess Margaret Cancer Centre Experience. SHILAP Revista de lepidopterología. 11(1). 41–48. 2 indexed citations
2.
Armstrong, Andrew J., Ravit Geva, Hyun Cheol Chung, et al.. (2024). CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial. Investigational New Drugs. 42(1). 145–159. 33 indexed citations
3.
Algazi, Alain P., Kyriakos P. Papadopoulos, Frank Tsai, et al.. (2024). Safety and clinical activity of durvalumab combined with tremelimumab in recurrent/metastatic head and neck squamous cell carcinoma: a multicenter phase I study. ESMO Open. 9(8). 103646–103646. 4 indexed citations
4.
Rose, April A. N., Ian King, Tong Zhang, et al.. (2024). Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations (mts): Final results of the investigator-initiated phase II BEAVER trial.. Journal of Clinical Oncology. 42(16_suppl). 3104–3104. 2 indexed citations
5.
Mittal, Abhenil, Xuan Li, Brian Moloney, et al.. (2023). The role of cytoreductive nephrectomy and systemic therapy in the management of tumour thrombus in patients with metastatic renal cell carcinoma. British Journal of Cancer. 128(10). 1888–1896. 5 indexed citations
6.
Lim, Emerson A., Michael T. Schweizer, Kim N., et al.. (2023). Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer. 21(3). 366–375. 32 indexed citations
7.
8.
Taylor, Kirsty, Jinfeng Zou, Marc Oliva, et al.. (2023). Circulating tumour DNA kinetics in recurrent/metastatic head and neck squamous cell cancer patients. European Journal of Cancer. 188. 29–38. 14 indexed citations
9.
O’Kane, Grainne M., Warren Mason, Pavlina Spiliopoulou, et al.. (2023). Circulating Oncometabolite 2-hydroxyglutarate as a Potential Biomarker for Isocitrate Dehydrogenase (IDH1/2) Mutant Cholangiocarcinoma. Molecular Cancer Therapeutics. 23(3). 394–399. 6 indexed citations
10.
Graham, Jeffrey, J. Connor Wells, Shaan Dudani, et al.. (2022). Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy. European Journal of Cancer. 171. 124–132. 20 indexed citations
11.
Yu, Eugene, Brian O’Sullivan, Jie Su, et al.. (2021). Prognostic importance of radiologic extranodal extension in nasopharyngeal carcinoma treated in a Canadian cohort. Radiotherapy and Oncology. 165. 94–102. 25 indexed citations
12.
Veitch, Zachary, Daniel Shepshelovich, Lisa Wang, et al.. (2021). Underreporting of Symptomatic Adverse Events in Phase I Clinical Trials. JNCI Journal of the National Cancer Institute. 113(8). 980–988. 40 indexed citations
13.
Kushnir, Igal, Naveen S. Basappa, Sunita Ghosh, et al.. (2021). Active Surveillance in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System. Clinical Genitourinary Cancer. 19(6). 521–530. 12 indexed citations
14.
Ren, Jianjun, Katrina Hueniken, Ghazal Haddad, et al.. (2021). Longitudinal health utility and symptom‐toxicity trajectories in patients with head and neck cancers. Cancer. 128(3). 497–508. 9 indexed citations
15.
Wells, J. Connor, Shaan Dudani, Gan Chen, et al.. (2020). Real-world clinical effectiveness of second-line sunitinib following immuno-oncology therapy in patients with metastatic renal cell carcinoma. European Urology Open Science. 19. e1105–e1106. 1 indexed citations
16.
Ribnikar, Domen, Igor Stukalin, Philippe L. Bédard, et al.. (2020). The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Metastatic Testicular Cancer. Current Oncology. 28(1). 107–114. 9 indexed citations
17.
Chen, Lina, Lisa Wang, Anna Spreafico, et al.. (2019). Characterization and outcomes of patients enrolled to multiple phase I cancer trials. Cancer Chemotherapy and Pharmacology. 85(2). 469–472. 1 indexed citations
18.
Ren, Jianjun, Jie Su, Rouhi Fazelzad, et al.. (2019). Human papillomavirus and p16 immunostaining, prevalence and prognosis of squamous carcinoma of unknown primary in the head and neck region. International Journal of Cancer. 145(6). 1465–1474. 24 indexed citations
19.
Lewin, Jeremy, Laleh Soltan Ghoraie, Philippe L. Bédard, et al.. (2018). Gene expression signatures prognostic for relapse in stage I testicular germ cell tumours. British Journal of Urology. 122(5). 814–822. 8 indexed citations
20.
Lassen, Ulrik, Didier Meulendijks, L.L. Siu, et al.. (2014). A Phase I Monotherapy Study of RG7212, a First-in-Class Monoclonal Antibody Targeting TWEAK Signaling in Patients with Advanced Cancers. Clinical Cancer Research. 21(2). 258–266. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Christophe Le Tourneau Breakdown of academic impact, for papers by Stephen Y. Lai Breakdown of academic impact, for papers by Sylvie Rottey Breakdown of academic impact, for papers by Amanda Psyrri Breakdown of academic impact, for papers by Carla M.L. van Herpen Breakdown of academic impact, for papers by A. Dimitrios Colevas Breakdown of academic impact, for papers by Lars Bastholt Breakdown of academic impact, for papers by Denis Soulières Breakdown of academic impact, for papers by Stefan M. Willems Breakdown of academic impact, for papers by Jonathan D. Cheng
Rankless by CCL
2026